S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David A. Hyman, MD, JD, on Inclusive Shared Savings

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Jul

Today In Oncology

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer

FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma

Study Reveals Long-Term Consequences of Chemotherapy on Healthy Blood Cells

Can Hormone Therapy Affect Breast Cancer Risk in Younger Women

Uterine Cancer Incidence and Mortality Rates Projected to Rise Substantially by 2050